Biotech and drug stocks, collectively, are down an average of 16% over the past three months. The closely watched XBI index ...

In the world of biotechnology investing, companies often struggle to bring new drugs to market. Developing treatments for rare diseases can be incredibly expensive, and because these conditions ...

Recursion Pharmaceuticals (NASDAQ:RXRX) is a biotech innovator who knows what ... to make a small, strategic investment in the firm back in 2023. But just because Nvidia and Cathie Wood have ...

I will start by saying that biotechnology is a game Changer, it has revolutionised various fields, including medicare, agricultural business, industrial engineering and environmental science, ...

CEO Tamer Mohamed told BIV he believes the investment climate in biotech is awful.Rob Kruyt, BIV “This is the worst funding climate for biotech in an entire generation,” he said.

Chicago Partners Investment Group LLC boosted its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 2.5% in the fourth quarter, according to its most recent Form 13F filing ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take a drubbing. But at OSE Immunotherapeutics, which aims to prevent ...

SAN FRANCISCO – Vir Biotechnology, Inc., a $1.5 billion market cap biotech company, announced a change in its executive team with the upcoming departure of Ann (Aine) M. Hanly, Ph.D., and the ...

The companies Immunovant, Verdiva Bio, and Akero Therapeutics bagged the biggest biotech funding rounds overall in January ...

FNY Investment Advisers LLC owned 1.74% of Lixte Biotechnology worth $82,000 at the end of the most recent reporting period. Lixte Biotechnology Price Performance Shares of LIXT opened at $2.45 on ...

Not only that, but activist investor Carl Icahn boosted his stake in a petroleum refiner, and another biotech company also had a beneficial owner return to the buy window. Let’s take a quick ...

Throughout my career, I have been struck by how often traditional media fails to grasp the critical nuances of biotech investing and catalyst trading, frequently leaving investors misinformed and ...